Answers are grounded in this paper and cite their sources.
Laboratory protocol demonstrates efficient CD19-CAR lentiviral transduction of adult and cord blood natural killer cells, indicating an accessible pathway for off-the-shelf antitumor immunotherapies.
Natural killer cells, or NK cells, are a type of cytotoxic lymphocyte critical to the innate immune system. The role that NK cells play is analogous to that of cytotoxic T cells in that they provide rapid responses to virus-infected cells and responses to tumor formation. Unmodified NK cells have long been used in various immunotherapies to treat different tumors, with only marginal success. However, in the last few years, NK cells modified to express chimeric antigen receptors (CAR-NK cells) have emerged as particularly ideal cellular platforms for antigen-specific antitumor agents. Unlike CAR-T cells, they do not elicit allogeneic responses or graft-versus-host disease and therefore can be administered to recipients with differing MHC expression. This article outlines protocols to obtain CD19-CAR-NK cells, focusing on the importance of obtaining and culturing a purified NK cell population and how to attain good transfection efficiency.
No takes yet. Share an insight, caveat, or question.
Herrera et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: